Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It is a typothypical Th1/Th17 disease that affects from 2 to 3% of the world population. Numerous are the drugs that can be used in our clinical practice; the choice of these drugs depends on the characteristics of the patient. Areas covered: Apremilast is the first oral small molecules to receive FDA approval for the treatment of adults with active psoriasis and psoriatic arthritis. It is a small-molecule that specifically inhibits the activity of cyclic AMP phosphodiesterase-4 (PDE4). Several analyses have been performed on data from phase III studies to assess apremilast safety and efficacy on psoriasis and psoriatic arthritis (PsA). Apremilast could also represent a treatment opportunity for those patients unresponsive to both systemic and biological agents or whose treatment was contraindicated. Expert opinion: For its safety profile and easy route of administration, apremilast may offer an oral treatment option for those patients that discontinue treatments because of ineffectiveness, intolerability or ineligibility to the currently available drugs.

Dattola, A., Del Duca, E., Saraceno, R., Gramiccia, T., & Bianchi, L. (2017). Safety evaluation of apremilast for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 16(3), 381-385 [10.1080/14740338.2017.1288714].

Safety evaluation of apremilast for the treatment of psoriasis

SARACENO, ROSITA;BIANCHI, LUCA
2017

Abstract

Psoriasis (PSo) is a chronic inflammatory skin disease associated with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It is a typothypical Th1/Th17 disease that affects from 2 to 3% of the world population. Numerous are the drugs that can be used in our clinical practice; the choice of these drugs depends on the characteristics of the patient. Areas covered: Apremilast is the first oral small molecules to receive FDA approval for the treatment of adults with active psoriasis and psoriatic arthritis. It is a small-molecule that specifically inhibits the activity of cyclic AMP phosphodiesterase-4 (PDE4). Several analyses have been performed on data from phase III studies to assess apremilast safety and efficacy on psoriasis and psoriatic arthritis (PsA). Apremilast could also represent a treatment opportunity for those patients unresponsive to both systemic and biological agents or whose treatment was contraindicated. Expert opinion: For its safety profile and easy route of administration, apremilast may offer an oral treatment option for those patients that discontinue treatments because of ineffectiveness, intolerability or ineligibility to the currently available drugs.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Con Impact Factor ISI
Dattola, A., Del Duca, E., Saraceno, R., Gramiccia, T., & Bianchi, L. (2017). Safety evaluation of apremilast for the treatment of psoriasis. EXPERT OPINION ON DRUG SAFETY, 16(3), 381-385 [10.1080/14740338.2017.1288714].
Dattola, A; Del Duca, E; Saraceno, R; Gramiccia, T; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
safety apremilast.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 2.93 MB
Formato Adobe PDF
2.93 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/174512
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact